PAPER Imai Y

Editorial: Molecular links between mitochondrial damage and human neurodegenerative disorders, volume II.

Front Cell Dev Biol. 2024;12:1417802. Epub 2024 Apr 29 PubMed.

PAPER Xu Y, Zhang J, Li X

Erjingwan and Alzheimer's disease: research based on network pharmacology and experimental confirmation.

Front Pharmacol. 2024;15:1328334. Epub 2024 Apr 29 PubMed.

PAPER Mansouri Z, Khodagholi F, Zaringhalam J, Abbaszadeh F, Ghasemi R, Maghsoudi N

Intranasal CEPO-FC prevents attention deficits in streptozotocin-induced rat model of Alzheimer's disease: Focus on synaptic plasticity-related factors.

EXCLI J. 2024;23:491-508. Epub 2024 Apr 22 PubMed.

PAPER Sampatakakis SN, Mourtzi N, Charisis S, Mamalaki E, Ntanasi E, Hatzimanolis A, Ramirez A, Lambert JC, Yannakoulia M, Kosmidis MH, Dardiotis E, Hadjigeorgiou G, Megalou M, Sakka P, Scarmeas N

Walking time and genetic predisposition for Alzheimer's disease: Results from the HELIAD study.

Clin Neuropsychol. 2024 May 13;:1-17. PubMed.

Marçal Vilar on APP C-Terminal Fragments Stifle Calcium Flow from ER to Lysosomes

COMMENT In this very interesting paper Bretou et al. described the toxic effect produced by the genetic and pharmacologic inhibition of the γ-secretase complex. The authors described that these treatments increased the levels of APP-CTF inducing a dysfunction of

Lixisenatide

THERAPEUTICS Sanofi Adlyxin Lyxumia Other Other In June 2018, French researchers started a Phase 2 study to evaluate the effect of lixisenatide in people with early Parkinson’s disease. The LixiPark trial enrolled 156 participants, with a target dose of 20 μg daily fo

Jourdan Parent on More Evidence that Locus Coeruleus Demise Precedes Cortical Tangles

COMMENT This study is really exciting because it used longitudinal neuroimaging to understand factors that lead to tau accumulation in the brain and to later cognitive decline. We already knew that structural integrity of the locus coeruleus, a brainstem region o

Executive Director, Alzheimer’s Disease Data Initiative

JOB 2024-05-14 Employer Gates Ventures Contact   mmaclean@talentongroup.com Description The goals of the AD Data Initiative are to encourage and enable interoperability across existing platforms; expand and enhance the community of data contributors and users; evaluate

Andreas Jeromin on FDA Will Regulate Diagnostic Tests. Yes, Those for Alzheimer’s, Too.

COMMENT Laboratory-developed test (LDTS) in the current framework are an important tool to accelerate innovation, in particular in rapidly evolving diagnostic markets such as AD. Understanding risks/benefits, the target, performance in racial populations, and mul

PAPER Banerjee R, Ghanty R, Jagtap S, Holla V, Kamble N, Yadav R, Pal PK, Datta I

Generation of induced pluripotent stem cells (NIMHi015-A) from a Parkinson's Disease patient harbouring a homozygous Exon 3 deletion in the PRKN gene.

Stem Cell Res. 2024 Jun;77:103440. Epub 2024 May 9 PubMed.

PAPER Xu F, Takiguchi Y, Makabe K, Konno H

Synthesis and evaluation of catecholamine derivatives as amyloid-beta aggregation inhibitors.

Bioorg Med Chem Lett. 2024 Jul 15;107:129788. Epub 2024 May 11 PubMed.

PAPER Blum D, Levi S

Targeting excitatory:inhibitory network imbalance in Alzheimer's disease.

Brain. 2024 Jun 3;147(6):1931-1933. PubMed.

PAPER Xin J, Huang S, Wen J, Li Y, Li A, Satyanarayanan SK, Yao X, Su H

Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis.

Aging Dis. 2024 May 8; PubMed.

PAPER Elmahboub YS, Elkordy AA

Polymeric nanoparticles: A promising strategy for treatment of Alzheimer's disease.

J Taibah Univ Med Sci. 2024 Jun;19(3):549-565. Epub 2024 Apr 26 PubMed.

Ayngarasoruoban Thalayarathenam

University of Hyderabad
Telangana, India